DIA413.88+2.83 0.69%
SPX5,663.94+32.66 0.58%
IXIC17,928.14+189.98 1.07%

Sharps Technology Gains ~$100K Initial Purchase Order From Hungarian Vaccine Provider For SecureGard Syringes

Benzinga·05/06/2025 11:05:18
Listen to the news

Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System

Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter

Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces the receipt of a $100,000 purchase order from a Hungarian vaccine provider. This order supports the recently announced $400,000 SoloGard™ order, which is part of a broader $50 million agreement that was previously announced with a U.S. company and represents the first SecureGard™ order from this Hungary-based company.

"I am pleased to announce our second significant purchase order to date, bringing our total orders received for Q2 to approximately $500,000," stated Robert Hayes, Chief Executive Officer of Sharps Technology. "These latest orders mark the first for our SecureGard and Disgard™ product lines, and we are excited to begin what we anticipate will be a long-term relationship with these customers. With this milestone, Sharps has officially transitioned into a commercial-stage company, which is a pivotal moment in our growth trajectory."

In addition to the recent order for SecureGard, Sharps also received an initial qualification order for the DisGard Sharps Recovery System - a compact, single-use surgical sharps container designed to support safe, point-of-use disposal in operating rooms and outpatient procedures. The system plays a vital role in surgical inventory recovery by securing small sharps immediately after use, helping healthcare providers reduce loss of surgical instruments and mitigate injury risks.

Mr. Hayes concluded: "SecureGard, SoloGard, and DisGard are all manufactured at our state-of-the-art facility in Hungary, where we currently maintain inventory levels to meet ongoing and future demand. We are well-positioned to execute on our expanding pipeline of purchase agreements and remain focused on scaling production and fulfillment. We look forward to keeping our shareholders informed as we continue building momentum and delivering on our strategic vision."

About SecureGard® Retractable Safety Syringe:

The SecureGard Retractable Safety Syringe is a single-use, sterile, disposable hypodermic syringe with a needle attached which is intended for dispensing/administering fluids in medical practice. The key safety feature, where the clinician retracts the hypodermic needle by manually locking the plunger onto the needle hub, withdrawing the plunger, pulling the needle into the barrel and breaking the plunger, virtually eliminates the accidental clinical reuse of the syringe and accidental needle stick injuries.

Advantages of SecureGard Retractable Needles:

  • Low dead space (LDS) – reduce drug wastage
  • No change in technique, requires minimal training
  • Manual retraction
  • Low-cost solution
  • Latex free
  • Breakaway plunger
  • Available in 1ml, 3ml and 5ml capacity
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.